Skip to content

Remifentanil_ Propofol versus Remifentanil_ Ketamine in Diagnostic Bronchoscopy

Hemodynamic Changes in Patients undergoing Diagnostic Bronchoscopy using Remifentanil_ Propofol versus Remifentanil_ Ketamine

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20171202037716N1
Enrollment
76
Registered
2017-12-13
Start date
2018-01-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedation for Diagnostic Bronchoscopy. Abnormal findings on diagnostic imaging of lung

Interventions

Intervention 1: Intervention group: Remifentanil 0.1 microgram/kg/min Intra venously 3 min Before Procedure plus Propofol 0.5 mg/kg Intra venously. Intervention 2: Intervention group: Remifentanil 0
Treatment - Other
Intervention group: Remifentanil 0.1 microgram/kg/min Intra venously 3 min Before Procedure plus Propofol 0.5 mg/kg Intra venously
Intervention group: Remifentanil 0.1 microgram/kg/min Intra venously 3 min Before Procedure plus Ketamine 0.25 mg/kg Intra venously

Sponsors

Ardabil University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 18 to 65 y/o Patients with Pulmonary Diseases ( ASA : 1_3 ) that selected by Pulmonologist for Diagnostic Bronchoscopy

Exclusion criteria

Exclusion criteria: Patients with Opioid addiction Untreated HTN or IHD Loss of Consciousness Epileptic Patients

Design outcomes

Primary

MeasureTime frame
Percent of Systolic Blood Pressure Rising after Drugs administeration. Timepoint: Record of Systolic Blood Pressure Before, During and After Procedure. Method of measurement: Non invasive Manometer.

Secondary

MeasureTime frame
Consciousness State of Patients. Timepoint: 10 minutes after end of Procedure. Method of measurement: Ramsey Sedation Score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDavood Seifi

Ardabil University of Medical Sciences

davood3565@gmail.com+98 45 3352 1355

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026